Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|October 23, 2014
Pharmacokinetics of single-agent axitinib across multiple solid tumor typesMichael A Tortorici, Ezra E W Cohen, Yazdi K Pithavala, et al.
Bioengineered|January 29, 2025
Targeted insertion of heterogenous DNA using Cas9-gRNA ribonucleoprotein-mediated gene editing in <i>Ganoderma lucidum</i>Hyerang Eom, Yeon-Jae Choi, Rutuja Nandre, et al.
Journal of Cancer Survivorship : Research and Practice|April 9, 2011
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinomaPeter C Trask, Andrew G Bushmakin, Joseph C Cappelleri, et al.
Journal of the American College of Emergency Physicians Open|April 2, 2025
Aggressive Behavior Risk Assessment Tool for Emergency Medical ServicesSon Chae Kim, Kathie Dunn, Corey Youells, et al.
Scientific Reports|July 10, 2023
The Cas9-gRNA ribonucleoprotein complex-mediated editing of pyrG in Ganoderma lucidum and unexpected insertion of contaminated DNA fragmentsHyerang Eom, Yeon-Jae Choi, Rutuja Nandre, et al.
Japanese Journal of Clinical Oncology|May 1, 2013
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trialTakeshi Ueda, Hirotsugu Uemura, Yoshihiko Tomita, et al.
Oncotargets and Therapy|June 20, 2015
Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational studyShukui Qin, Feng Bi, Jie Jin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinomaBrian I Rini, George Wilding, Gary Hudes, et al.
Clinical Genitourinary Cancer|March 31, 2015
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell CarcinomaBernard Escudier, Brian I Rini, Robert J Motzer, et al.
Investigational New Drugs|December 6, 2016
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumorsMuhammad S Beg, Andrew J Brenner, Jasgit Sachdev, et al.
Pageof 6